

16 Dec 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ambros-therapeutics-launches-with-125-million-series-a-financing-to-advance-neridronate-through-phase-3-registrational-program-for-complex-regional-pain-syndrome-type-1-302642798.html